Clinical Trial Update: A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 platform trial evaluating immunomodulatory compounds for patients with non-small cell lung cancer that is refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Non-Small Cell Lung Cancer, ICI-refractory | Phase 2 | Status: RECRUITING